CD62L-depleted effector memory T cells

CD62L-depleted effector memory T cells (Tem) are an adoptive cellular therapy developed by University College London (UCL) to facilitate immune reconstitution and prevent infections in patients undergoing allogeneic stem cell transplantation. The therapy involves the infusion of donor-derived T cells that have been selectively depleted of CD62L-positive (L-selectin) naive and central memory T cells using clinical-grade immunomagnetic selection. Naive T cells are the primary mediators of graft-versus-host disease (GVHD), while the remaining CD62L-negative effector memory T cells retain the ability to provide protective immunity against opportunistic pathogens (such as CMV, EBV, and adenovirus) and exert potential graft-versus-leukemia effects. This approach, evaluated in the ToTem trial, aims to provide the benefits of donor lymphocyte infusion while minimizing the risk of GVHD.

Other names

CD62L-negative effector memory T cellsCD-62L-negative effector memory T cellsCD 62L-negative effector memory T cellsDonor effector memory T cellsToTem